Back

Real-world effectiveness of mineralocorticoid receptor antagonists in heart failure with mildly reduced and preserved ejection fraction: a large southeast asian propensity-weighted cohort study

29 August 2026 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: Moving the needle further in HFrEF therapy Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Porntep Amornritvanich

Police General Hospital, Bangkok (Thailand)

5 More presentations in this session

Presentation thumbnail
Efficacy of sacubitril/valsartan on mortality in asymptomatic hypotensive HFrEF: data from the China Cardiovascular Association Database-Heart Failure Center Registry
Doctor Z. Qiu (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Superior cardiorenal protection with tirzepatide over dulaglutide in heart failure with preserved ejection fraction: a large-scale propensity score–matched real-world analysis
Doctor I. Zahan (Harefield, GB)
Abstract Slides
Presentation thumbnail
The FINO-HF trial: a randomised comparison of finerenone versus spironolactone in patients with heart failure with reduced ejection fraction - biomarker and clinical outcomes
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides
Presentation thumbnail
The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides
Presentation thumbnail
Glucagon-like peptide-1 receptor agonism in heart failure with improved ejection fraction; PRAISE-HFiEF
Assistant Professor I. Helmy (Cleveland, US)
Abstract Slides

Access the full session

Session thumbnail
Moving the needle further in HFrEF therapy
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
The mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction
29 June 2021
thumbnail
Congress Presentation
What is the adherence to ARNI and iSGLT2 treatment in heart failure patients with reduced ejection fraction in a real world population?
29 June 2021
thumbnail
Congress Presentation
Comparative analysis of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitor and mineralocorticoid receptor antagonists in heart failure with mildly reduced ejection fraction
1 September 2024
thumbnail
Congress Presentation
Hospital readmission and mortality in chinese patients with heart failure stratified by ejection fraction levels after treatment with sacubitril/valsartan
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources